GLP-1 receptor agonists alter NAD+ metabolism through weight loss and direct cellular signaling. Researchers studying NAD+ pathways must account for this confounder.

Define the confounding pathway

GLP-1 receptor agonists reduce food intake and body weight. Weight loss changes NAD+ levels in tissues. This creates a confounding variable in NAD+ studies.

GLP-1 signaling also activates sirtuins. Sirtuins consume NAD+ as a co-substrate. This direct effect confounds NAD+ measurements independent of weight change.

Screen participants for GLP-1 use

Ask every participant about prescription medication use. Include GLP-1 receptor agonists by name in screening forms. Semaglutide tirzepatide and liraglutide are common examples.

Published research shows GLP-1 agonist use ranges from something like 5-15% in metabolic studies. In obesity-focused cohorts the prevalence can reach 30-50%. Screening must be specific not generic.

Exclude or stratify by GLP-1 status

Exclusion is the simplest control method. Exclude anyone taking a GLP-1 receptor agonist within 90 days. This washout period allows weight and metabolic effects to stabilize.

Stratification preserves sample size. Assign participants to GLP-1 user or non-user strata. Analyze NAD+ outcomes within each stratum separately. This approach requires larger enrollment.

Measure GLP-1 agonist exposure directly

Self-report is unreliable for medication adherence. Measure plasma GLP-1 agonist levels by LC-MS/MS. This confirms exposure and quantifies dose.

For semaglutide the half-life is roughly one week. A single missed dose can alter NAD+ measurements. Direct measurement reduces misclassification bias.

Adjust for weight change as a mediator

Weight loss is a mediator not a confounder. Adjusting for weight change can introduce collider bias. Use causal diagrams to decide on adjustment.

If weight loss is on the causal pathway from GLP-1 to NAD+ then do not adjust. If weight loss is a common cause of GLP-1 use and NAD+ then adjust. The literature on NAD+ and weight suggests both pathways exist.

Control for sirtuin activation

GLP-1 agonists activate SIRT1 and SIRT3. These sirtuins consume NAD+ and lower its concentration. Measure sirtuin activity in tissue samples.

Published research shows SIRT1 activation reduces NAD+ levels by 20-40% in hepatocytes. This effect is independent of weight loss. Include sirtuin activity as a covariate in regression models.

Use matched control groups

Match GLP-1 users to non-users on baseline characteristics. Match on age sex BMI and baseline NAD+ levels. This reduces confounding by indication.

Propensity score matching is a common method. Calculate the probability of GLP-1 use from baseline covariates. Match each user to one or more non-users with similar scores.

Apply inverse probability weighting

Inverse probability weighting reweights the sample. Each participant receives a weight equal to the inverse of their probability of GLP-1 use. This creates a pseudo-population where GLP-1 use is independent of confounders.

Weights can be unstable with small samples. Trim extreme weights at the 1st and 99th percentiles. Published research shows this reduces variance without large bias.

Conduct sensitivity analyses

Sensitivity analyses test the robustness of findings. Vary the definition of GLP-1 exposure. Use any use ever current use or cumulative dose.

Also vary the washout period. Compare 30-day 60-day and 90-day exclusions. If results are stable across definitions confidence increases.

Report GLP-1 use transparently

Describe screening methods in the methods section. Report the number of excluded participants for GLP-1 use. Report the number of users in each stratum.

State whether GLP-1 use was an exclusion criterion or a stratification factor. This allows readers to assess generalizability. All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.

Consider peptide comparators in NAD+ studies

Some NAD+ studies include peptide interventions like Vesugen or MOTS-c. These peptides may interact with GLP-1 signaling. Standardizing NAD+ sampling in exercise trials with MOTS-c requires similar confounder control.

Vesugen is a short peptide studied for vascular effects. Its influence on NAD+ metabolism is not fully characterized. Blinding Vesugen administration in rodent studies helps reduce bias when Cerebrolysin is the comparator.

Epitalon and Thymosin Alpha-1 are also used in aging research. Their effects on NAD+ pathways may overlap with GLP-1 agonists. Control for all peptide exposures in the same way.

Document limitations

Residual confounding is possible even with careful control. Unmeasured variables like diet composition or exercise may differ between groups. Acknowledge this limitation in the discussion.

GLP-1 agonist use may change over time. A participant may start or stop the medication during the study. Repeated screening at each visit reduces this risk.

Researchers conducting independent work should follow institutional protocols and ethics review where applicable.